ERBB2 and adenocarcinoma: Molecular testing for many targetable genetic markers is now considered routine practice in the management of advanced adenocarcinoma, including activating mutations in epidermal growth factor (EGFR), BRAF, Her2, MET exon 14 splicing, NTRK, ERBB2, KRAS and rearrangements of anaplastic lymphoma kinase (ALK) and ROS proto-oncogene1 (ROS1) [3,4,5].